News & Updates
Showing Gastroenterology articles
Showing
Show Multimedia Only

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
09 May 2026
byStephen Padilla
Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.








